Table 1.

Transfection efficiency in clinical-scale cell product manufacture from HVs and CGD patients

Cell sourcemRNACell number, ×106GFP+/gp91+/p47+, % of product
HV1 GFP 297.8 95.9 
HV2 GFP 297.3 91 
HV3 GFP 152.1 88.9 
Gp91phox− CGD Gp91 344.4 74.7 
Gp91phox− CGD GFP 110.8 94.6 
P47phox− CGD P47 334.3 88.3 
P47phox− CGD GFP 85.3 98.7 
Cell sourcemRNACell number, ×106GFP+/gp91+/p47+, % of product
HV1 GFP 297.8 95.9 
HV2 GFP 297.3 91 
HV3 GFP 152.1 88.9 
Gp91phox− CGD Gp91 344.4 74.7 
Gp91phox− CGD GFP 110.8 94.6 
P47phox− CGD P47 334.3 88.3 
P47phox− CGD GFP 85.3 98.7 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal